These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12209478)

  • 21. Clinical trials. Nail-biting time for trials of COX-2 drugs.
    Couzin J
    Science; 2004 Dec; 306(5702):1673-5. PubMed ID: 15576585
    [No Abstract]   [Full Text] [Related]  

  • 22. A side effect of COX-2 inhibitors.
    Harv Health Lett; 2003 Apr; 28(6):7. PubMed ID: 12777233
    [No Abstract]   [Full Text] [Related]  

  • 23. Celecoxib shown effective in preventing colon polyps.
    Nelson NJ
    J Natl Cancer Inst; 2006 May; 98(10):665-7. PubMed ID: 16705118
    [No Abstract]   [Full Text] [Related]  

  • 24. The Vioxx debacle revisited.
    Abeles M; Abeles AM
    Am J Med; 2005 Sep; 118(9):1057-8. PubMed ID: 16164907
    [No Abstract]   [Full Text] [Related]  

  • 25. Painful lessons.
    Nat Struct Mol Biol; 2005 Mar; 12(3):205. PubMed ID: 15744317
    [No Abstract]   [Full Text] [Related]  

  • 26. [Financial interests characterize published reports on coxiber. Whom can we rely on?].
    Håkansson J
    Lakartidningen; 2002 Oct; 99(40):3930-1. PubMed ID: 12422746
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Institutional review boards must conduct safety review.
    Maloney DM
    Hum Res Rep; 2005 Feb; 20(2):3. PubMed ID: 15839005
    [No Abstract]   [Full Text] [Related]  

  • 31. [Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered].
    MMW Fortschr Med; 2003 Mar; 145(10):60. PubMed ID: 12688036
    [No Abstract]   [Full Text] [Related]  

  • 32. [COX-2 inhibitors--one step forward and two steps back].
    Evensen S; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cyclooxygenase-2 inhibitors and the ethics of research].
    Gherardi CR
    Medicina (B Aires); 2005; 65(5):476. PubMed ID: 16296649
    [No Abstract]   [Full Text] [Related]  

  • 35. Cardiovascular effects of cyclooxygenase-2 inhibitors.
    Brophy JM
    Curr Opin Gastroenterol; 2007 Nov; 23(6):617-24. PubMed ID: 17906437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How safe are your prescription pills?
    Gorman C
    Time; 2001 Sep; 158(9):50-1. PubMed ID: 11550614
    [No Abstract]   [Full Text] [Related]  

  • 37. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
    Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COX-2 inhibition and thrombotic tendency.
    Fenn CG
    Med J Aust; 2002 Jan; 176(2):88-9; author reply 89. PubMed ID: 11936297
    [No Abstract]   [Full Text] [Related]  

  • 39. Rofecoxib, Merck, and the FDA.
    Wolfe MM
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-inflammatory drugs may put on the pressure.
    Harv Heart Lett; 2003 Mar; 13(7):7. PubMed ID: 12654586
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.